Sanofi has entered into a research collaboration and license agreement with Lead Pharma to discover, develop and commercialize small-molecule therapies directed against the nuclear hormone receptors called ROR gamma t to treat a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease, which are among the most common.
|Searching for more deal information? Current Partnering offers the following options:|
Sanofi and Lead Pharma will collaborate during the early phase of research and development with a goal of identifying drug candidates and beginning human trials within 3-4 years.
Lead Pharma will receive an upfront payment and is eligible to receive research, development, regulatory and commercial milestone payments.
Sanofi will be responsible for clinical development and have worldwide marketing and commercialization rights to any products that may be developed as a result of the collaboration.
Lead Pharma is entitled to receive royalty payments on global sales from any such products.
Further details of the financial terms have not been disclosed.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies